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Summary
 
Experimental allergic encephalomyelitis (EAE) is an autoimmune disease of the central nervous
system (CNS), and the most commonly used experimental model for multiple sclerosis. It is
mediated by autoreactive T cell clones exhibiting a T helper cell (Th) 1 cytokine profile. Non-
encephalitogenic T lymphocytes specific for self or exogenous antigens have been found to
suppress encephalitogenic T cell responses and to protect against autoimmune disease. The
mechanisms by which exogenous antigens modulate autoimmunity are not fully understood. In
this study, we tested the hypothesis that a Th2-type immune response against an exogenous,
nonself antigen, keyhole limpet hemocyanin (KLH), by releasing IL-4 in the microenviron-
ment, could shift the cytokine profile of encephalitogenic T cells from an inflammatory Th1 to
a protective Th2 type. SJL/J mice were preimmunized with the KLH in incomplete Freund’s
adjuvant to induce a population of Th2 memory cells that would be expected to release Th2
cytokines when activated by the specific antigen at the time of EAE induction. Four weeks
later, mice received an encephalitogenic challenge containing guinea pig myelin in complete
Freund’s adjuvant with or without KLH. All KLH primed animals not receiving the exogenous
antigen at the time of EAE induction developed a severe clinical disease indistinguishable from
control mice not KLH primed. In contrast, animals preimmunized and challenged with the en-
cephalitogenic inoculum containing KLH showed either no, or markedly reduced, clinical
signs. Enzyme-linked immunospot analysis demonstrated that KLH-specific T cells in the
primed mice were producing IL-4 characteristic of Th2 cells. In the KLH-primed and restimu-
lated mice, the cytokine profile of the autoreactive, myelin basic protein–specific T cells was shifted
from an inflammatory Th1 towards a protective Th2 type. We infer that the presence of IL-4
secreted by KLH-specific memory Th2 cells in the lymphoid system microenvironment in
which the autoreactive T cells were engaged by the encephalitogenic stimulus were able to bias
their cytokine profile towards a protective Th2 phenotype. This interpretation is supported by
the observation that the protective effect of preimmunization with KLH was overcome by rm–
IL-12, which inhibited the production of IL-4 by the Th1 cells and biased the autoimmune
response to a predominantly Th1 type. Since IL-4 mRNA could not be detected by reverse
transcriptase PCR in the CNS, the protective effect was inferred to be mediated by Th2 cells
in the lymphoid system, and not the target organ. We conclude that exogenous, nonself anti-
gens that can induce Th2 responses, can modify the cytokine environment sufficiently to alter
the cytokine phenotype of inflammatory, autoreactive T cell clones, and ultimately, to provide
significant protection against EAE and possibly other T cell–mediated autoimmune diseases.
and proteolipid protein (1, 2). Encephalitogenic T cell
clones have a classical Th1 cytokine profile, secreting the
cytokines IFN-
 
g
 
 and IL-2, and induce local macrophage
activation, inflammation, and demyelination (3, 4). Th2 cell
clones specific for encephalitogenic peptides are unable to
induce the disease and can inhibit Th1 autoimmune clones,
presumably by secreting IL-4, IL-10, and TGF-
 
b
 
 (5–8). In
a transgenic mouse model, the presence of lymphocytes ex-
 
1
 
Abbreviations used in this paper: 
 
CNS, central nervous system; EAE, exper-
imental allergic encephalomyelitis; ELISPOT, enzyme-linked immuno-
spot; HPRT, hypoxanthine phosphoribosyl transferase; MBP, myelin ba-
sic protein; rm, recombinant murine; RT, reverse transcriptase.
 
E
 
xperimental allergic encephalomyelitis (EAE)
 
1
 
 is an au-
toimmune disease of the central nervous system (CNS)
mediated by CD4
 
1
 
 T lymphocytes specific for autoantigens
of the myelin sheath, including myelin basic protein (MBP)
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pressing a transgenic TCR specific for MBP was not suffi-
cient to induce the autoimmune disease. Rather, these
transgenic mice developed spontaneous EAE only when
the RAG-1 gene was deleted and the transgenic, MBP-
specific T cells were present in a context in which no other
lymphocytes expressing different T cell receptors existed
(9, 10). This observation supports the view that the patho-
genicity of predetermined autoimmune T cells can be effec-
tively modulated by lymphocytes of other specificities.
Infectious agents have often been implicated in the etiol-
ogy of autoimmune diseases (11), and considerable evidence
has accumulated indicating that immune responses to for-
eign antigens are able to modulate the activation of au-
toimmune T cell clones. For example, it has been shown
that the immune response against bacterial antigens can at-
tenuate the outcome of experimental autoimmune diseases
such as adjuvant arthritis, insulin-dependent diabetes melli-
tus in NOD mice, and EAE in mice and rats (12–18). In
several studies, administration of mycobacterial proteins
such as heat-shock cognate proteins of 65 and 70 kD, a
12-kD protein, or tuberculin PPD in IFA, induced protec-
tion against EAE (19–21). Understanding the mechanisms
involved in the modulation of experimental autoimmune
diseases could provide insights into immunologic strategies for
developing useful interventions in human autoimmune diseases.
At present, the mechanisms responsible for protection
against autoimmune diseases induced by microbial antigens
remain unclear. One hypothesis to explain how an im-
mune response against an exogenous antigen may interfere
with autoimmunity holds that the bacterial proteins may
induce a state of tolerance, as suggested by a downregula-
tion of the CD4 coreceptor detected at the time of onset of
the autoimmune disease in mice protected by treatment
with mycobacterial hsp60 (19). In this paper we test an al-
ternative hypothesis, namely, that the immunization against
nonself antigens can inhibit the development of EAE by
modifying the cytokine environment in which autoreactive
T cell clones develop and expand upon autosensitization,
such that their cytokine profile is shifted from an inflamma-
tory Th1 towards a protective Th2 type.
 
Materials and Methods
 
Mice.
 
Female SJL/J mice (8–12-wk old) were purchased from
the Jackson Laboratory (Bar Harbor, ME). Animals were housed
in the animal facility of the Albert Einstein College of Medicine,
maintained on standard laboratory chow and water ad libitum,
and were free of 12 murine pathogens. The experiments were
done in accordance to the animal use guidelines of the National
Institutes of Health.
 
Antigens.
 
The guinea pig myelin was purified from guinea
pig spinal cords (Pel-Freeze, Rockland, PA) according to the
method of Norton and Poduslo (22). KLH of 
 
Megathura crenulata
 
was purchased from Calbiochem Corp. (San Diego, CA) and bo-
vine MBP from Sigma Chemical Co. (St. Louis, MO).
 
Preimmunization with KLH.
 
SJL/J mice were injected intra-
peritoneally 4 wk before the induction of EAE with 50 
 
m
 
g of
KLH emulsified in IFA (Difco Labs., Detroit, MI). Control mice
received PBS at the same time.
 
Induction of EAE.
 
SJL/J mice were injected in four different
sites in the back with 0.1 ml of inoculum containing 700 
 
m
 
g of
guinea pig myelin in CFA (700 
 
m
 
g/ml of 
 
Mycobacterium tuberculo-
sis 
 
H37Ra strain in IFA). One group of mice received again the
KLH antigen (50 
 
m
 
g) with the encephalitogenic inoculum. All
groups of mice received 100 ng of pertussigen/mouse intrave-
nously on days 0, 2, and 7.
 
Clinical Evaluation.
 
Mice were monitored daily and a clinical
score was assigned using the following scale (23): 0, no clinical
sign; 1, a limp tail; 2, hind limb weakness; 3, complete hind limb
paralysis; 4, tetraplegia; 5, death.
 
Recombinant Murine IL-12.
 
The recombinant murine (rm) IL-12
(Genetics Institute, Boston, MA) was administered intraperito-
neally at 0.3 
 
m
 
g/mouse on days 0, 1, and 2 p.i. to a group of SJL/J
mice pretreated with the KLH antigen that received a second
KLH immunization at the time of EAE induction (24).
 
Establishment of KLH- and MBP-specific T Cell Lines.
 
Axillar and
inguinal lymph nodes were removed 10 d p.i., homogenized,
pooled, and resuspended (4 
 
3
 
 10
 
6
 
/ml) in RPMI 1640 (GIBCO
BRL, Gaithersburg, MD) supplemented with 10% FCS, 100 U/ml
penicillin/streptomycin, 2 mM glutamine, 15 mM Hepes, 100 
 
m
 
M
nonessential amino acids, 1 mM Na-pyruvate, and 50 
 
m
 
M 2-mer-
captoethanol. Cells were stimulated with KLH or MBP (50 
 
m
 
g/
ml) for 6 d at 37
 
8
 
C in 5% CO
 
2
 
.
 
Determination of Cytokine Profiles of Specific T Cell Lines by En-
zyme-linked Immunospot.
 
An adaptation of the enzyme-linked
immunospot (ELISPOT) assay (25) was used to enumerate IFN-
 
g
 
and IL-4 secreting T cells among the KLH- and MBP-specific
short-term lines. In brief, 96-well nitrocellulose based plates (Mil-
lititer HA; Millipore Corp., Bedford, MA) were coated overnight
with mAb anti-murine IL-4 or IFN-
 
g
 
 mAbs (10 
 
m
 
g/ml; Phar-
Mingen, San Diego, CA). The plates were washed with PBS, and
the T cell lines were purified on ficoll-hypaque and added to in-
dividual wells at serial twofold dilutions (2 
 
3
 
 10
 
5
 
–6 
 
3
 
 10
 
3
 
). Sple-
nocytes from donor SJL/J mice were negatively selected for
CD3
 
1
 
 T cells using a rat anti–murine CD3 mAb (GIBCO BRL)
and magnetic beads coated with antibodies to rat IgG (DYNAL,
Inc., Great Neck, NY), irradiated, and added to the plate (5 
 
3
 
10
 
4
 
/well) together wth Con A (2.5 
 
m
 
g/ml). After 20 h, the plates
were washed with PBS containing 0.05% Tween and incubated
overnight with biotinylated mAbs anti–IL-4 or anti–IFN-
 
g
 
 (4
 
m
 
g/ml). The plates were then washed with PBS–Tween and in-
cubated with avidin-peroxidase (2.5 
 
m
 
g/ml). Spots representing
single IL-4– or IFN-
 
g
 
–secreting T cells were developed with the
substrate 3-amino-9-ethylcarbazole in 0.1 M sodium acetate
buffer 
 
1
 
 H
 
2
 
O
 
2
 
. The number of spots was enumerated using a dis-
secting microscope.
 
Determination of Cytokine Profiles in the CNS by Quantitative Re-
verse Transcriptase–PCR.
 
The CNS of KLH-protected and con-
trol EAE mice were removed 18 d p.i., and the total RNA was
extracted using TRIzol Reagent (GIBCO BRL). RNA samples
were reverse transcribed using random hexamers (GIBCO BRL)
as primers and Superscript reverse transcriptase (GIBCO BRL).
The cDNA was then amplified with the following specific prim-
ers: hypoxanthine phosphoribosyl transferase (HPRT), 5
 
9
 
-GTTG-
GATACAGGCCAGACTTTGTTG, 3
 
9
 
-GAGGGTAGGCTGG-
CCTATGGCT; IFN-
 
g
 
, 5
 
9
 
-TGCATCTTGGCTTTGCAGCTC-
TTCCTCATGGC, 3
 
9
 
-TGGACCTGTGGGTTGTTGACCTCA-
AACTTGGC; IL-4, 5
 
9
 
-CATCGGCATTTTGAACGAGGTCA,
3
 
9
 
-CTTATCGATGAATCCAGGCATCG. To normalize the
amount of cDNA, we performed a quantitative PCR analysis of
HPRT mRNA levels using serial dilution of the pQRS poly-
competitor (provided by Dr. D.B. Corry, University of Califor- 
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nia at San Francisco, San Francisco, CA; 26). The amount of
IFN-
 
g
 
–specific RNA in the two cDNA normalized samples was
measured by quantitative PCR using serial dilutions of the mouse
IFN-
 
g
 
 PCR MIMIC (Clontech, Palo Alto, CA). Reactions were
performed in a programmable thermal controller (Perkin-Elmer
Cetus Instrs., Norwalk, CT) for 35 cycles. Each cycle consisted of
94
 
8
 
C for 40 s, 60
 
8
 
C for 20 s, and 72
 
8
 
C for 40 s. After amplifica-
tion, 10 
 
m
 
l of PCR product was separated by electrophoresis on
1% agarose gels and visualized by ethidium bromide staining.
 
Results
 
Priming and Challenge of Mice with an Exogenous Antigen,
KLH, in IFA Induces Protection from EAE.
 
To test the hy-
pothesis that T cells specific for a foreign antigen could al-
ter the course of EAE in SJL/J mice, two groups of mice
were primed intraperitoneally with KLH in IFA. A control
group received PBS at the same time. After 4 wk all mice
received an encephalitogenic inoculum containing guinea
pig myelin in CFA, and one of the two groups of mice pre-
viously primed with KLH received the KLH antigen at this
time. EAE was fully developed after 10–14 d in the animals
that were not primed, or that received the KLH in IFA 4
wk before but were not given the foreign antigen at the
time of the encephalitogenic immunization. In contrast,
when the KLH-specific T cells were reactivated at the time
of EAE induction by a second antigenic challenge, the KLH-
primed mice were almost completely protected. In this group
of mice, both the incidence and the mean clinical score were
significantly reduced compared to controls (Fig. 1). These
results indicated that stimulating primed mice with the
nonself antigen at the time of activation of autoimmune T
cell clones could alter the course of the autoimmune disease.
 
Protection Against EAE Is Abolished when the KLH-primed
Mice Are Treated with rmIL-12.
 
To test the hypothesis that
the protection induced by the KLH was due to a shift in
the cytokine profile of the encephalitogenic clones from a
Th1 to a Th2 type, we attempted to reverse the KLH effect
by modifying the cytokine profiles of the KLH- and MBP-
specific T cells in the KLH protected mice. Since previous
studies established that IL-12, the major Th1 “priming” cy-
tokine, is able to inhibit KLH-specific memory Th2 cells in
primed mice (27), we treated the KLH-primed and chal-
lenged mice with rmIL-12. SJL/J mice were preimmu-
nized with KLH as before. After 4 wk the exogenous anti-
gen was given again with encephalitogenic inoculum and,
at the same time, a portion of the mice were treated for three
consecutive days with rmIL-12. In these mice, the KLH-
induced protection was completely abolished, and, in fact, the
mice receiving IL-12 showed even greater mean clinical
score than the control, non-KLH primed mice (Fig. 2).
 
KLH-specific T Cells in KLH-preimmunized Mice Have a
 
Th2 Cytokine Profile.
 
To verify our hypothesis that KLH
administered in IFA induces the Th2 response that alters
the nature of autoimmune T cells, we examined the cyto-
kine profiles of both KLH- and MBP-specific T cell lines
in these mice. T cells were isolated from lymph nodes from
the three groups of animals at 10 d p.i. and stimulated in
vitro with KLH or MBP, the predominant autoantigen in
EAE. After 6 d, the cytokine profiles of these short-term
lines directly obtained from the animals were determined
by ELISPOT. As expected, the KLH-specific T cells from
animals preimmunized intraperitoneally with KLH in IFA
showed a predominantly Th2 phenotype. In contrast, when
the KLH-primed mice were treated with rmIL-12, both
IFN-
 
g
 
– and IL-4–producing cells were found among the
KLH-specific T cells, but the number of IL-4 secreting T
cells was consistently decreased (Fig. 3 
 
a
 
). In control mice
not primed with KLH, the KLH-specific T cells receiving
the first antigenic stimulus in vitro, expressed a Th1 profile.
This indicated that primary antigenic stimulation of naive
T cells with KLH in vitro leads to a predominantly Th1
phenotype.
Figure 1. Effect of the KLH preimmunization and challenge at the
time of EAE induction on the incidence and clinical score of the disease.
Two groups of SJL/J mice were injected intraperitoneally with an emul-
sion of KLH in IFA. One control group was injected with PBS. After
4 wk, EAE was induced by immunizing the animals with guinea pig my-
elin in CFA. One of the two groups of mice pretreated with KLH re-
ceived the foreign antigen with the encephalitogenic inoculum. This group
of mice was almost completely protected (filled circles) against EAE. The
control group that was not preimmunized with KLH (open circles) or the
group that was primed, but not challenged a second time with KLH (open
squares) both showed high incidences and clinical scores for the disease. 
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In the Protected, KLH-primed Mice, the Cytokine Profile of the En-
cephalitogenic T Cells Is Shifted Towards a Th2 Type.
 
Among the
MBP-specific T cell lines isolated from lymph nodes, the
number of IL-4–secreting T cells was significantly higher in
the KLH-protected mice compared to the controls (Fig. 3
 
b
 
). The number of IFN-
 
g
 
–producing, inflammatory Th1
cells in these mice is very low, a result consistent with the
protection against EAE that we observed. When the KLH-
primed and challenged mice were treated for 3 d with
rmIL-12, the cytokine profile of the MBP-specific T cells was
reversed to a predominantly inflammatory Th1 type (Fig. 3 
 
b
 
).
 
Th2 Autoreactive Cells Are Not Found in the CNS.
 
We
sought to address the question whether the protective ef-
fect on EAE induced by KLH-specific Th2 cells was medi-
ated centrally or in the CNS target organ. Histopathologi-
cal analysis of the brain and spinal cords of KLH-protected
and control mice confirmed a lower degree of lymphocyte
infiltration in the CNS of the protected mice, consistent
with the reduced clinical score (data not shown). To deter-
mine the cytokine profile phenotype of the T cells found in
the CNS, we performed a reverse transcriptase (RT)-PCR
analysis on the total RNA samples extracted from brains
and spinal cords of both groups of mice. After normaliza-
tion for HRPT DNA, we evaluated IL-4 and IFN-
 
g
 
mRNA expression in the two samples. No IL-4 RNA ex-
pression was found in either group of mice. The amount of
IFN-
 
g
 
 expression was measured by quantitative PCR. As
expected, the attomoles per microgram of IFN-
 
g
 
 mRNA
was significantly lower in the protected mice (5 
 
3
 
 10
 
2
 
2
 
 at-
tomoles) than in the control (1.2 
 
3
 
 10
 
2
 
1
 
 attomoles). Al-
though the failure to detect the IL-4 mRNA expression in
the brain of the protected mice does not allow us formally
to exclude the possibility that Th2 cells enter the CNS, the
data support the interpretation that the downregulation of
Th1 inflammatory clones takes place in the lymph nodes at
the time of autoantigenic stimulation, so that a lower number
of Th1 encephalitogenic clones develop and reach the CNS.
Figure 2. rmIL-12 at the time of immunization overcomes protection
engendered by pretreatment and reticulation with KLH. One group of
mice that was pretreated with KLH in IFA received the antigen again
with the encephalitogenic inoculum together with rmIL-12 (0.3 mg/
mouse), given on days 0, 1, and 2 after immunization (filled squares). The
mice receiving the minimal treatment with rmIL-12 were not protected
against EAE and showed a significantly higher mean clinical score com-
pared to the KLH-protected mice (filled circles).
Figure 3. Determination of cytokine profiles of KLH (a) and MBP (b) specific short-term T cell lines. Two mice of each group were killed at day 10
p.i. and lymph node cells stimulated in vitro with KLH or MBP for 6 d. The number of IL-4 (crosshatched bars) and IFN-g (solid bars) was determined by
ELISPOT analysis. The KLH-specific lymph node T cells of mice immunized with the antigen in IFA showed a Th2 cytokine profile. When the mice
were treated with rmIL-12, the number of IL-4–producing cells was decreased. In control mice receiving only PBS, the primary antigenic stimulation in
vitro with KLH induced a Th1 phenotype. The MBP-specific T cells showed a Th1 inflammatory profile in nonprotected controls (not pretreated with,
or not restimulated with KLH) while in KLH-protected mice, the cytokine profile was shifted to a Th2 type. Treatment with rmIL-12 for only 3 d was
sufficient to modify the phenotype of the MBP-specific T cells in the KLH/IFA-treated mice from Th2 from Th1. 
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Discussion
 
Autoreactive T lymphocytes are present in the T cell
repertoire of healthy individuals and the mechanisms that
modulate their activation in T cell–mediated autoimmune
diseases remain unclear. Multiple lines of evidence suggest
that simultaneous T cell immune responses against nonself
antigens, for example, during infections, may modulate the
activity of autoreactive T cell clones. Epidemiological stud-
ies have clearly shown that environmental factors play a role
in the pathogenesis of human autoimmune diseases (28, 29).
Experimental studies on transgenic mice expressing the MBP
T cell receptor indicate that the ability of the encephalito-
genic clones to induce EAE is modulated by lymphocytes
with different specificity, presumably specific for antigens
present in the environment (9, 10). Most of these studies
have stressed the ability of immune responses to environ-
mental antigens to activate the autoreactive T cells (30–32)
and induce disease, but in a number of cases, it has been
observed that responses against exogenous antigens can down-
regulate the encephalitogenic T cell clones (17–21). Several
laboratories have reported that immunization with myco-
bacterial proteins such as PPD, 
 
hsp
 
65, and 
 
hsp
 
70 can confer
protection against EAE, but the mechanisms responsible for
this protection have not been elucidated. Another example
of downmodulation of autoimmune T cell clones by an ex-
ogenous antigen is the protection against EAE reported
after oral administration of ovalbumin (33). Although a
“bystander suppression” mechanism mediated by Th2 cy-
tokines has been proposed, a shift in the cytokine profile of
the autoreactive T cells was not clearly demonstrated, and
other immunosuppressive cytokines such as TGF-
 
b
 
 and IL-10
were implicated in the protection induced.
Several attempts have been made to shift the cytokine
profile of autoimmune T cell clones from a Th1 to a Th2
type, for example, by oral administration of the autoantigen
(5), or targeting of the encephalitogenic peptide of MBP
on B cells (34), and recently by modifying of the amino
acid sequence of the encephalitogenic peptide (35). In most
such studies, protection against EAE and clinical disease
was observed, but a shift in cytokine profiles of the autore-
active T clones from an inflammatory Th1 to a protective
Th2, IL-4–producing phenotype has not been clearly
shown. At the present time, the mechanisms that regulate
the Th1 or Th2 differentiation remain to be clarified, and
currently only the presence of “priming” cytokines such as
IL-12 or IL-4, in the microenvironment where the naive
T cells receive their primary antigenic stimulus, appears to
be determinative (36). In other systems it has been demon-
strated that Th1 and Th2 subsets with different antigen speci-
ficities can interact in vivo. In particular, Th2-type immune
responses against parasitic agents can alter Th1 responses to
mycobacterial antigens and viruses by an IL-4–dependent
mechanism (37–40).
Previous studies have shown that the administration of
an antigen in IFA biases the response towards a Th2 phe-
notype, while CFA more likely induces a Th1 cytokine
profile in T helper cells (41). In our model, we find that the
production of Th2 cells, defined by the ability to produce
IL-4, induced by an exogenous antigen by administration
in IFA was sufficient to prime for a cytokine microenvi-
ronment in which the autoimmune stimulus was modu-
lated to an attenuated or protective one. This finding indi-
cates that the exogeneous antigen need not be a cognate
 
hsp
 
 or cross-reactive with autoantigens to supress EAE.
When the effect of IL-4 was countered by the administra-
tion of IL-12, the protection provided by the KLH-spe-
cific, Th2 cells was abrogated. However, our findings sug-
gest that the modulation of the response mediated by
exogenous antigen occurs in the lymphoid system rather
than the target organ, since by RT-PCR we were unable to
detect IL-4 mRNA in the CNS, although IFN-
 
g
 
 mRNA
was readily detectable in the control group that developed
EAE. This observation suggests that Th2 autoreactive cells
either do not reach, or are not retained in the CNS. Our
interpretation is that MBP-specific Th2 cells do not induce
inflammation in the CNS and, at the same time, inhibit the
Th1 autoreactive clones at the level of the peripheral
lymph nodes such that fewer are developed or migrate to
the CNS. This is indicated by the lower amount of IFN-
 
g
 
mRNA we found in the CNS of the KLH-protected mice.
In summary, our data suggest a mechanism for modula-
tion of disease-causing autoimmune T cell clones develop-
ment by Th2 cells specific for nonself antigens. We believe
that a Th2-type immune response against an exogenous an-
tigen modulates the autoimmune disease by modifying the
Figure 4. IFN-g and IL-4
mRNA in the CNS of KLH-
protected and control mice sen-
sitized to myelin. The RT-PCR
was performed on RNA samples
extracted from brain and spinal
cord of the mice at day 16 after
immunization using specific primers
for IFN-g and IL-4. The mRNAs
for IFN-g and IL-4 were mea-
sured by quantitative PCR using
a competitor DNA fragment for
each, and the quantities expressed
as attomoles of cDNA per mi-
crogram of total RNA. 
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cytokine environment at the time of primary autoantigenic
stimulation of the autoreactive T cell clones, shifting their
cytokine profile from an inflammatory Th1 to a protective
Th2 type. These findings may serve to clarify the role of Th2
immune responses against exogenous antigens, such as those
found to occur during parasitic infections, in modulating
the pathogenesis of Th1-mediated autoimmune diseases. At
the same time, because of obvious risks in immunizing in-
dividuals with specific autoantigens to prevent autoimmu-
nity, they provide further support for the possibility of modu-
lating the cytokine profile of encephalitogenic T cell clones
by means of exogenous antigens to induce protection in
experimental autoimmune diseases of CNS, and encourage
the view that it may ultimately be possible to modify the
immune responses of autoreactive T cell clones therapeutically
to prevent or attenuate human T cell–mediated autoimmune
diseases.
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